Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society

Andrew M.D. Wolf, Elizabeth T.H. Fontham, Timothy R. Church, Christopher R. Flowers, Carmen E. Guerra, Samuel J. LaMonte, Ruth Etzioni, Matthew T. McKenna, Kevin C. Oeffinger, Ya Chen Tina Shih, Louise C. Walter, Kimberly S. Andrews, Otis W. Brawley, Durado Brooks, Stacey A. Fedewa, Deana Manassaram-Baptiste, Rebecca L. Siegel, Richard C. Wender, Robert A. Smith

Research output: Contribution to journalArticle

173 Citations (Scopus)

Abstract

In the United States, colorectal cancer (CRC) is the fourth most common cancer diagnosed among adults and the second leading cause of death from cancer. For this guideline update, the American Cancer Society (ACS) used an existing systematic evidence review of the CRC screening literature and microsimulation modeling analyses, including a new evaluation of the age to begin screening by race and sex and additional modeling that incorporates changes in US CRC incidence. Screening with any one of multiple options is associated with a significant reduction in CRC incidence through the detection and removal of adenomatous polyps and other precancerous lesions and with a reduction in mortality through incidence reduction and early detection of CRC. Results from modeling analyses identified efficient and model-recommendable strategies that started screening at age 45 years. The ACS Guideline Development Group applied the Grades of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria in developing and rating the recommendations. The ACS recommends that adults aged 45 years and older with an average risk of CRC undergo regular screening with either a high-sensitivity stool-based test or a structural (visual) examination, depending on patient preference and test availability. As a part of the screening process, all positive results on noncolonoscopy screening tests should be followed up with timely colonoscopy. The recommendation to begin screening at age 45 years is a qualified recommendation. The recommendation for regular screening in adults aged 50 years and older is a strong recommendation. The ACS recommends (qualified recommendations) that: 1) average-risk adults in good health with a life expectancy of more than 10 years continue CRC screening through the age of 75 years; 2) clinicians individualize CRC screening decisions for individuals aged 76 through 85 years based on patient preferences, life expectancy, health status, and prior screening history; and 3) clinicians discourage individuals older than 85 years from continuing CRC screening. The options for CRC screening are: fecal immunochemical test annually; high-sensitivity, guaiac-based fecal occult blood test annually; multitarget stool DNA test every 3 years; colonoscopy every 10 years; computed tomography colonography every 5 years; and flexible sigmoidoscopy every 5 years. CA Cancer J Clin 2018;68:250–281.

Original languageEnglish (US)
Pages (from-to)250-281
Number of pages32
JournalCA Cancer Journal for Clinicians
Volume68
Issue number4
DOIs
StatePublished - Jul 1 2018
Externally publishedYes

Fingerprint

Early Detection of Cancer
Colorectal Neoplasms
Guidelines
Patient Preference
Colonoscopy
Life Expectancy
Incidence
Guaiac
Adenomatous Polyps
Sigmoidoscopy
Neoplasms
Occult Blood
Hematologic Tests
Health Status
Cause of Death
History
Tomography
Mortality
DNA
Health

Keywords

  • adenoma, colonoscopy
  • colorectal and rectal neoplasms
  • computed tomography colonoscopy
  • mass screening and early detection
  • mortality
  • occult blood
  • radiography
  • sigmoidoscopy
  • stool testing

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Wolf, A. M. D., Fontham, E. T. H., Church, T. R., Flowers, C. R., Guerra, C. E., LaMonte, S. J., ... Smith, R. A. (2018). Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer Journal for Clinicians, 68(4), 250-281. https://doi.org/10.3322/caac.21457

Colorectal cancer screening for average-risk adults : 2018 guideline update from the American Cancer Society. / Wolf, Andrew M.D.; Fontham, Elizabeth T.H.; Church, Timothy R.; Flowers, Christopher R.; Guerra, Carmen E.; LaMonte, Samuel J.; Etzioni, Ruth; McKenna, Matthew T.; Oeffinger, Kevin C.; Shih, Ya Chen Tina; Walter, Louise C.; Andrews, Kimberly S.; Brawley, Otis W.; Brooks, Durado; Fedewa, Stacey A.; Manassaram-Baptiste, Deana; Siegel, Rebecca L.; Wender, Richard C.; Smith, Robert A.

In: CA Cancer Journal for Clinicians, Vol. 68, No. 4, 01.07.2018, p. 250-281.

Research output: Contribution to journalArticle

Wolf, AMD, Fontham, ETH, Church, TR, Flowers, CR, Guerra, CE, LaMonte, SJ, Etzioni, R, McKenna, MT, Oeffinger, KC, Shih, YCT, Walter, LC, Andrews, KS, Brawley, OW, Brooks, D, Fedewa, SA, Manassaram-Baptiste, D, Siegel, RL, Wender, RC & Smith, RA 2018, 'Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society', CA Cancer Journal for Clinicians, vol. 68, no. 4, pp. 250-281. https://doi.org/10.3322/caac.21457
Wolf, Andrew M.D. ; Fontham, Elizabeth T.H. ; Church, Timothy R. ; Flowers, Christopher R. ; Guerra, Carmen E. ; LaMonte, Samuel J. ; Etzioni, Ruth ; McKenna, Matthew T. ; Oeffinger, Kevin C. ; Shih, Ya Chen Tina ; Walter, Louise C. ; Andrews, Kimberly S. ; Brawley, Otis W. ; Brooks, Durado ; Fedewa, Stacey A. ; Manassaram-Baptiste, Deana ; Siegel, Rebecca L. ; Wender, Richard C. ; Smith, Robert A. / Colorectal cancer screening for average-risk adults : 2018 guideline update from the American Cancer Society. In: CA Cancer Journal for Clinicians. 2018 ; Vol. 68, No. 4. pp. 250-281.
@article{9c1601e16d324b179b33c64781f78133,
title = "Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society",
abstract = "In the United States, colorectal cancer (CRC) is the fourth most common cancer diagnosed among adults and the second leading cause of death from cancer. For this guideline update, the American Cancer Society (ACS) used an existing systematic evidence review of the CRC screening literature and microsimulation modeling analyses, including a new evaluation of the age to begin screening by race and sex and additional modeling that incorporates changes in US CRC incidence. Screening with any one of multiple options is associated with a significant reduction in CRC incidence through the detection and removal of adenomatous polyps and other precancerous lesions and with a reduction in mortality through incidence reduction and early detection of CRC. Results from modeling analyses identified efficient and model-recommendable strategies that started screening at age 45 years. The ACS Guideline Development Group applied the Grades of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria in developing and rating the recommendations. The ACS recommends that adults aged 45 years and older with an average risk of CRC undergo regular screening with either a high-sensitivity stool-based test or a structural (visual) examination, depending on patient preference and test availability. As a part of the screening process, all positive results on noncolonoscopy screening tests should be followed up with timely colonoscopy. The recommendation to begin screening at age 45 years is a qualified recommendation. The recommendation for regular screening in adults aged 50 years and older is a strong recommendation. The ACS recommends (qualified recommendations) that: 1) average-risk adults in good health with a life expectancy of more than 10 years continue CRC screening through the age of 75 years; 2) clinicians individualize CRC screening decisions for individuals aged 76 through 85 years based on patient preferences, life expectancy, health status, and prior screening history; and 3) clinicians discourage individuals older than 85 years from continuing CRC screening. The options for CRC screening are: fecal immunochemical test annually; high-sensitivity, guaiac-based fecal occult blood test annually; multitarget stool DNA test every 3 years; colonoscopy every 10 years; computed tomography colonography every 5 years; and flexible sigmoidoscopy every 5 years. CA Cancer J Clin 2018;68:250–281.",
keywords = "adenoma, colonoscopy, colorectal and rectal neoplasms, computed tomography colonoscopy, mass screening and early detection, mortality, occult blood, radiography, sigmoidoscopy, stool testing",
author = "Wolf, {Andrew M.D.} and Fontham, {Elizabeth T.H.} and Church, {Timothy R.} and Flowers, {Christopher R.} and Guerra, {Carmen E.} and LaMonte, {Samuel J.} and Ruth Etzioni and McKenna, {Matthew T.} and Oeffinger, {Kevin C.} and Shih, {Ya Chen Tina} and Walter, {Louise C.} and Andrews, {Kimberly S.} and Brawley, {Otis W.} and Durado Brooks and Fedewa, {Stacey A.} and Deana Manassaram-Baptiste and Siegel, {Rebecca L.} and Wender, {Richard C.} and Smith, {Robert A.}",
year = "2018",
month = "7",
day = "1",
doi = "10.3322/caac.21457",
language = "English (US)",
volume = "68",
pages = "250--281",
journal = "CA Cancer Journal for Clinicians",
issn = "0007-9235",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Colorectal cancer screening for average-risk adults

T2 - 2018 guideline update from the American Cancer Society

AU - Wolf, Andrew M.D.

AU - Fontham, Elizabeth T.H.

AU - Church, Timothy R.

AU - Flowers, Christopher R.

AU - Guerra, Carmen E.

AU - LaMonte, Samuel J.

AU - Etzioni, Ruth

AU - McKenna, Matthew T.

AU - Oeffinger, Kevin C.

AU - Shih, Ya Chen Tina

AU - Walter, Louise C.

AU - Andrews, Kimberly S.

AU - Brawley, Otis W.

AU - Brooks, Durado

AU - Fedewa, Stacey A.

AU - Manassaram-Baptiste, Deana

AU - Siegel, Rebecca L.

AU - Wender, Richard C.

AU - Smith, Robert A.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - In the United States, colorectal cancer (CRC) is the fourth most common cancer diagnosed among adults and the second leading cause of death from cancer. For this guideline update, the American Cancer Society (ACS) used an existing systematic evidence review of the CRC screening literature and microsimulation modeling analyses, including a new evaluation of the age to begin screening by race and sex and additional modeling that incorporates changes in US CRC incidence. Screening with any one of multiple options is associated with a significant reduction in CRC incidence through the detection and removal of adenomatous polyps and other precancerous lesions and with a reduction in mortality through incidence reduction and early detection of CRC. Results from modeling analyses identified efficient and model-recommendable strategies that started screening at age 45 years. The ACS Guideline Development Group applied the Grades of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria in developing and rating the recommendations. The ACS recommends that adults aged 45 years and older with an average risk of CRC undergo regular screening with either a high-sensitivity stool-based test or a structural (visual) examination, depending on patient preference and test availability. As a part of the screening process, all positive results on noncolonoscopy screening tests should be followed up with timely colonoscopy. The recommendation to begin screening at age 45 years is a qualified recommendation. The recommendation for regular screening in adults aged 50 years and older is a strong recommendation. The ACS recommends (qualified recommendations) that: 1) average-risk adults in good health with a life expectancy of more than 10 years continue CRC screening through the age of 75 years; 2) clinicians individualize CRC screening decisions for individuals aged 76 through 85 years based on patient preferences, life expectancy, health status, and prior screening history; and 3) clinicians discourage individuals older than 85 years from continuing CRC screening. The options for CRC screening are: fecal immunochemical test annually; high-sensitivity, guaiac-based fecal occult blood test annually; multitarget stool DNA test every 3 years; colonoscopy every 10 years; computed tomography colonography every 5 years; and flexible sigmoidoscopy every 5 years. CA Cancer J Clin 2018;68:250–281.

AB - In the United States, colorectal cancer (CRC) is the fourth most common cancer diagnosed among adults and the second leading cause of death from cancer. For this guideline update, the American Cancer Society (ACS) used an existing systematic evidence review of the CRC screening literature and microsimulation modeling analyses, including a new evaluation of the age to begin screening by race and sex and additional modeling that incorporates changes in US CRC incidence. Screening with any one of multiple options is associated with a significant reduction in CRC incidence through the detection and removal of adenomatous polyps and other precancerous lesions and with a reduction in mortality through incidence reduction and early detection of CRC. Results from modeling analyses identified efficient and model-recommendable strategies that started screening at age 45 years. The ACS Guideline Development Group applied the Grades of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria in developing and rating the recommendations. The ACS recommends that adults aged 45 years and older with an average risk of CRC undergo regular screening with either a high-sensitivity stool-based test or a structural (visual) examination, depending on patient preference and test availability. As a part of the screening process, all positive results on noncolonoscopy screening tests should be followed up with timely colonoscopy. The recommendation to begin screening at age 45 years is a qualified recommendation. The recommendation for regular screening in adults aged 50 years and older is a strong recommendation. The ACS recommends (qualified recommendations) that: 1) average-risk adults in good health with a life expectancy of more than 10 years continue CRC screening through the age of 75 years; 2) clinicians individualize CRC screening decisions for individuals aged 76 through 85 years based on patient preferences, life expectancy, health status, and prior screening history; and 3) clinicians discourage individuals older than 85 years from continuing CRC screening. The options for CRC screening are: fecal immunochemical test annually; high-sensitivity, guaiac-based fecal occult blood test annually; multitarget stool DNA test every 3 years; colonoscopy every 10 years; computed tomography colonography every 5 years; and flexible sigmoidoscopy every 5 years. CA Cancer J Clin 2018;68:250–281.

KW - adenoma, colonoscopy

KW - colorectal and rectal neoplasms

KW - computed tomography colonoscopy

KW - mass screening and early detection

KW - mortality

KW - occult blood

KW - radiography

KW - sigmoidoscopy

KW - stool testing

UR - http://www.scopus.com/inward/record.url?scp=85047765381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047765381&partnerID=8YFLogxK

U2 - 10.3322/caac.21457

DO - 10.3322/caac.21457

M3 - Article

C2 - 29846947

AN - SCOPUS:85047765381

VL - 68

SP - 250

EP - 281

JO - CA Cancer Journal for Clinicians

JF - CA Cancer Journal for Clinicians

SN - 0007-9235

IS - 4

ER -